REMS For Mavacamten Could Involve Additional Monitoring, BMS Says
User Fee Delayed; Potential For Systolic Dysfunction Needs Watching
The FDA will take three more months to review mavacamten, a treatment for hypertrophic cardiomyopathy that BMS expects to be one of the company’s next blockbusters.
